Tumor Treating Fields therapy could potentiate immunotherapy in non-small-cell lung cancer.

Lancet Oncol

NIHR Biomedical Research Centre Leicester and Cancer Research UK Experimental Cancer Centre, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester LE2 7LX, UK. Electronic address:

Published: September 2023

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(23)00394-7DOI Listing

Publication Analysis

Top Keywords

tumor treating
4
treating fields
4
fields therapy
4
therapy potentiate
4
potentiate immunotherapy
4
immunotherapy non-small-cell
4
non-small-cell lung
4
lung cancer
4
tumor
1
fields
1

Similar Publications

Background: Cancer is a leading cause of global mortality, accounting for nearly 10 million deaths in 2020. This is projected to increase by more than 60% by 2040, particularly in low- and middle-income countries. Yet, palliative and psychosocial oncology care is very limited in these countries.

View Article and Find Full Text PDF

Background: Virtual follow-up (VFU) has the potential to enhance cancer survivorship care. However, a greater understanding is needed of how VFU can be optimized.

Objective: This study aims to examine how, for whom, and in what contexts VFU works for cancer survivorship care.

View Article and Find Full Text PDF

Objective: The objective of this study was to discuss the characteristics of intracranial extension in patients with juvenile nasopharyngeal angiofibroma (JNA) and propose and an algorithm for its management.

Methods: A retrospective chart review of all patients with JNA who underwent operations between January 2013 and January 2023 was done, and those cases with intracranial extension categorized as stage IIIb, IVa, and IVb according to the Andrews modification of the Fisch staging classification were included in the study. Data were collected about age at presentation, symptoms, radiological findings, routes of intracranial extension, therapeutic management, and follow-up.

View Article and Find Full Text PDF

Pacific Peoples' Experiences of Cancer and Its Treatment in Aotearoa New Zealand Through Talanoa: A Qualitative Study of Samoan and Tongan Participants.

JCO Glob Oncol

January 2025

Auckland Regional Cancer and Blood Service, Te Toka Tumai Auckland, Health New Zealand, Te Whatu Ora, Auckland, New Zealand.

Purpose: In Aotearoa New Zealand, there are inequitable outcomes for Pacific peoples who experience higher rates of preventable cancers and poorer survival compared with other ethnicities. The aim of this study was to explore Pacific peoples lived experience of cancer and its treatment in the Auckland setting.

Methods: Data were collected through semistructured interviews (talanoa) with Pacific patients under the Auckland Regional Cancer and Blood Service.

View Article and Find Full Text PDF

Purpose: Immune checkpoint inhibitors (ICIs) have demonstrated promise in the treatment of various cancers. Single-drug ICI therapy (immuno-oncology [IO] monotherapy) that targets PD-L1 is the standard of care in patients with advanced non-small cell lung cancer (NSCLC) with PD-L1 expression ≥50%. We sought to find out if a machine learning (ML) algorithm can perform better as a predictive biomarker than PD-L1 alone.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!